Volasertib Combined With Induction Chemotherapy in Acute Myeloid Leukemia

Phase 1 Withdrawn Massachusetts General Hospital Boehringer Ingelheim · collab

NaSingle-groupOpen-labelTreatment

Summary

The study intervention involved in this study is the addition of a dose of volasertib as a part of the initial chemotherapy regimen for AML. The trial will involve a combination of the following drugs: * Volasertib (the study drug) * Idarubicin * Cytarabine

Timeline

Start: 2016-09
Primary completion: 2017-02
Completion: 2017-02

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Volasertib	Small molecule	—	Intravenous
Background	Cytarabine	Small molecule	—	—
Background	Idarubicin	Small molecule	—	Intravenous

Volasertib Combined With Induction Chemotherapy in Acute Myeloid Leukemia

Summary

Timeline

Drugs

Indications